Summary
Gilead Sciences, Inc. (GILD) announced a significant strategic collaboration and investment with Galapagos NV, a European biotechnology company. This agreement, effective July 14, 2019, involves an upfront payment of $3.95 billion and an equity investment of approximately $1.1 billion to gain access to Galapagos' extensive portfolio of current and future drug candidates. The collaboration focuses on developing and commercializing Galapagos' innovative pipeline, particularly in inflammatory diseases and other therapeutic areas. This move signals Gilead's intent to bolster its R&D pipeline with promising early-stage assets and diversify its therapeutic focus. The agreement grants Gilead options to license exclusive rights to all of Galapagos' clinical programs for a decade, with the potential for extensions. Gilead will share development costs equally and hold exclusive commercialization rights outside of the EU, Iceland, Norway, Liechtenstein, and Switzerland. Key programs included are GLPG-1690 for idiopathic pulmonary fibrosis and GLPG-1972 for osteoarthritis. The financial commitment underscores Gilead's strategic pivot towards acquiring late-stage and early-stage innovation to drive future growth.
Key Highlights
- 1Gilead entered into a comprehensive Option, License and Collaboration Agreement with Galapagos NV.
- 2Gilead will make an upfront payment of $3.95 billion and an equity investment of approximately $1.1 billion.
- 3The agreement provides Gilead with option rights to license all current and future clinical programs of Galapagos for 10 years.
- 4Gilead gains exclusive global commercialization rights outside of specific European countries for optioned programs.
- 5The collaboration includes immediate co-development of Galapagos' GLPG-1690 (autotaxin inhibitor for IPF) and GLPG-1972 (ADAMTS-5 inhibitor for osteoarthritis).
- 6Gilead will make additional payments and royalties based on the successful development and commercialization of Galapagos' pipeline programs.
- 7The transaction is subject to customary closing conditions, including antitrust clearances.